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Abstract Background Factor VIII (FVIII) trough levels> 1 IU/dL in patients with severe hemo-
philia A receiving regular prophylaxis may optimize bleed protection.
Objectives In this post hoc analysis of patients receiving tertiary prophylaxis for
approximately 1 year, the relationship between estimated FVIII levels and reported
bleeds was investigated to predict the potential for zero bleeds.
Methods Sixty-three patients (median [range] age, 28 [7–59] years) with severe
hemophilia A (229 bleeds) were included. FVIII levels at time of each bleed were
estimated from single-dose individual pharmacokinetics. The highest estimated FVIII
level at which patients experienced a bleed was considered the “potentially effective
trough level” for that bleed type. Kaplan–Meier estimates of proportions of patients
with no bleeds above certain estimated FVIII levels were determined. Those not
experiencing a bleed in the trial were assumed to have a bleed at 0 IU/dL (pragmatic
approach) or at their median trough level (conservative approach).
Results Kaplan–Meier estimates based on pragmatic approach predicted zero all
bleeds, joint bleeds, and spontaneous joint bleeds in 1 year in 40, 43, and 63% of
patients, respectively, when the potentially effective trough FVIII level was set at
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Introduction
Patients with severe hemophilia A have a deficiency of coagu-
lation factorVIII (FVIII) characterizedby recurrentspontaneous
and trauma-induced joint and soft-tissue bleeds. Hemarthro-
ses cause progressive arthropathy, chronic pain, and musculo-
skeletaldisability.1,2Standard treatment is to reduceorprevent
bleedswith regular infusions of FVIII, a practice called prophy-
laxis. Prophylactic infusions of FVIII should be started in young
children before, or at the time of, their first hemarthrosis.3,4 In
young children, this treatment strategy has been shown to
reduce or prevent joint bleeds and arthropathy.5,6
The original concept for prophylaxis was to infuse FVIII on a
regular basis to convert the bleeding phenotype from that of
severe hemophilia to one of moderate hemophilia. The hypoth-
esiswas thatmaintaining the FVIII trough level> 1 IU/dLwould
limit the number of spontaneous joint bleeds and thus decrease
joint damage.7 Although this practice is associated with a
markedreduction in thenumberofbleeds, itdoesnotcomplete-
ly eradicate spontaneous joint bleeds in all patients, and joint
disease has still been observed in young adults over a 25- to 30-
year period.8,9 Although the role of the FVIII trough level in
reducing the risk of breakthrough bleeding is undoubtedly
important, other parameters that play a role are now known,
including theamountof timespentat lowFVIII levels10andpeak
FVIII levels.11 The annualized number of joint bleeds experi-
enced by a patient with hemophilia is related to their baseline
FVIII level; the number of bleeds decreases rapidly as the FVIII
level increases from< 1toapproximately3 IU/dL, andcontinues
to fall until the FVIII level has reachedapproximately 12 IU/dL.12
Prophylaxis is used routinely in children, and is now
becoming standard care for adults with severe hemophilia
A.13 If prophylaxis is started later in life, it is inevitable that
arthropathy will have developed and target joints may be
present. This may affect the efficacy of prophylaxis and
influence the level of FVIII required to prevent bleeds.
The level of FVIII required to prevent all bleeds in patients
with severe hemophilia A is not well described and will vary
between individuals (pharmacokinetic [PK] profile, level of
activity). It is likely that patients starting tertiary prophylax-
is will have active target joints with established arthropathy,
and in this situation, higher FVIII levels may be needed to
prevent spontaneous joint bleeds, at least initially. To inves-
tigate the relationship between FVIII levels and bleeds, we
performed a post hoc analysis of data derived from a study of
patients initiated on tertiary prophylaxis14 (i.e., regular
continuous treatment started after the onset of joint disease
documented by physical examination and plain radiographs
of the affected joints15). The data set was used to predict FVIII
trough levels that could be potentially effective in the
prevention of all bleeds and spontaneous joint bleeds in
patients receiving regular prophylaxis. Prevention of all
bleeds is a measure of the overall protection provided and
prevention of spontaneous bleeds is arguably the minimum
outcome expected of a prophylactic treatment regimen.
Methods
Clinical Study Summary
Details of the prophylaxis study of antihemophilic factor
(recombinant; ADVATE; Baxalta US Inc., a member of the
Takeda group of companies, Lexington, Massachusetts, United
States; NCT00243386) have been described previously.14 This
multicenter, randomized, two-arm study compared annual-
izedbleeding rates (ABRs)betweentwoprophylactic treatment
regimens (standard prophylaxis or PK-guided prophylaxis).
To meet key inclusion criteria for initiation of tertiary
prophylaxis, patients needed to be aged! 7 and< 65 years,
have moderately severe or severe hemophilia A (baseline FVIII
level" 2 IU/dL), have received on-demand treatment for! 12
months with a minimum of 150 exposure days to FVIII con-
centrates, and havehad aminimumof eight joint hemorrhages
before enrollment. Jointdiseasewas inferredby thepresenceof
target joints. After awashout period of! 72hours, all enrolled
patients underwent a PK study consisting of an intravenous
bolus infusion with 50# 5 IU/kg of antihemophilic factor (re-
combinant) followed by 10 postinfusion venous blood samples
up to 48 hours after infusion. Of the 82 enrolled patients, 66
were randomized to one of the two prophylactic regimens
following 6 months of on-demand treatment in the trial. The
randomization at 6 months was stratified according to the
presence of target joints, defined as joints inwhich at least four
hemorrhages had occurred within a period of 6 months, or in
which> 20 lifetime hemarthroses had occurred. Patients
assigned to standard prophylaxis received 20 to 40 IU/kg of
antihemophilic factor (recombinant) every other day—the
precise dosage determined by the investigator on the basis of
the individual patient’s FVIII half-life, incremental recovery,
and clinical status. This resulted in a median measured FVIII
trough level of 3 IU/dL.14 Patients assigned to PK-guided pro-
phylaxis received 20 to 80 IU/kg of antihemophilic factor
(recombinant) every 72hours, with the aim of achieving a
FVIII trough level of 1 IU/dL.
Post Hoc Analysis of the Relationship between Bleeds
and Estimated FVIII Levels at the Time of Each Bleed
This post hoc analysis only included patients with severe
hemophilia A (defined as having at least one observed FVIII
level of< 1 IU/dL during the study) who were treated with
1 IU/dL. Between 1 and 10 IU/dL, every 1 IU/dL rise in estimated FVIII level was
associated with an additional 2% of patients having zero all bleeds.
Conclusion This post hoc analysis confirms benefits with trough levels of approxi-
mately 1 to 3 IU/dL in most patients starting tertiary prophylaxis; prophylaxis with
higher trough levels may help patients to achieve zero bleeds.
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prophylaxis for! 180 days. Bleeds were self-reported by
patients, and descriptions of bleeding episodes (including
etiology [spontaneous and traumatic/injury-related], severity,
and anatomical site[s]) were recorded in patient diaries and
verifiedby the investigator. Theseverityof thebleedingepisode
was determined by the following scale: (1) minor: little or no
pain; little or no change in the range ofmotion of affected joint
(if joint bleeding event); mild restriction of mobility and
activity; (2) moderate: mild to moderate pain; some decrease
in range of motion of affected joint (if joint bleeding event);
moderate decrease inmobility and activity; and (3)major/life-
threatening: significant pain; substantial decrease in range of
motionofaffectedjoint (if joint bleedingevent); incapacity; life
threatening.
A total of 63 patients and 229 bleeds were eligible for
analysis.Of the63patients includedintheanalysis,41recorded
at least one bleed during the prophylactic treatment period.
Estimation of FVIII Level at the Time of Each Bleed
Patient-specific PK profiles were obtained from the patients’
FVIIIactivity levelmeasurementscollectedduring thePKstudy.
Each patient had between 7 and 10 postinfusion FVIII activity
levelmeasurements. A two-compartmentalmodel, parameter-
ized in terms of macro constants with a Poisson error, was
fitted independently to the postinfusion PK data from each
patient using iteratively reweighted least squares with SAS
(Base SAS 9.3 Procedures Guide, Second Edition, and SAS/STAT
12.1User’sGuide;2012;SAS Institute Inc., Cary,NorthCarolina,
United States) and R (R: a language and environment for
statistical computing; 2019; R Development Core Team, R
Foundation for Statistical Computing, Vienna, Austria). If this
model did not converge, or the resulting estimates (such as
those of FVIII half-life) were unrealistic, then a one-compart-
mentalmodel, also parameterized in terms ofmacro constants
with a Poisson error, was fitted using iteratively reweighted
least squares. The goodness-of-fit plots were examined to
deem the suitability of this model. There were 12 missing
date-time values for bleeds and 9 missing date-time values for
infusions; thesevalueswere imputedusing analgorithmbased
on median values for the analysis. A sensitivity analysis was
undertaken to understand the impact of imputed date-time
values, which was found to beminimal when the analysis was
rerun, with entries with missing date-time values deleted.
The individually fitted PK model, along with the dose and
time of prophylactic infusions, was used to model the FVIII
activity levels through the duration of the study for each
patient. Thismodelwas used to estimate the FVIII level at the
time of each bleed as reported by the patient.
Estimation of the FVIII level at the time of each bleed was
based on the following assumptions:
1. The FVIII activity level–time profile could be suitably
characterized by a compartmental model.
2. PK were linear, implying dose-proportionality.
3. There was no interoccasion variability: this is negligible
on the basis of Björkman et al.16
4. Residual FVIII activity level was suitably accounted for
under the principle of superposition.
5. The constant underlying risk of bleed for each patient (i.e.,
physical activity or sports) was not taken into account.
Modeling Bleed Prevention in Relation to Estimated
FVIII Levels Associated with Bleeds
Threebleed typeswere considered in the analyses: all bleeds,
joint bleeds, and spontaneous joint bleeds. For each patient,
the highest FVIII activity level at which they experienced
each type of bleed during prophylactic treatment was con-
sidered their “potentially effective trough level” for that
bleed type, above which the patient would likely be bleed
free.
During prophylactic treatment, some patients did not
experience any bleeds at all, whereas others did not experi-
ence bleeds of certain types. To avoid biasing the results by
removing patients from the analysis who did not experience
a bleed (type), an assumption was made regarding the level
at which these patients may be expected to bleed (if FVIII
trough levels dropped below a certain threshold). Analyses
were performed using pragmatic and conservative
approaches for these patients:
Pragmatic (“Best-Case”) Approach
The pragmatic approach assumed that patients who did not
experience a bleed (type) would have had a bleed (of that
type) only if their FVIII levelwas 0 IU/dL. Doseswere selected
to achieve a trough level of 1 IU/dL (known to be associated
with decreased bleeding tendency); therefore, not all
patients would be expected to experience levels of< 1 IU/dL
during the period of prophylaxis.10,12,17
Conservative (“Worst-Case”) Approach
The conservative approach assumed that patients who did
not experience a bleed (type) would have had a bleed (of that
type) if their FVIII level fell below their median estimated
trough level. This approach errs on the side of caution
because patients did not actually experience a bleed at their
median trough level; it assumes that FVIII levels maintained
throughout the period of prophylaxis were at least equal to
or greater than the median trough level.
Results
Patient Characteristics
Of the 66 patients with severe (n¼ 58) or moderately severe
(n¼ 8) hemophilia A randomized to one of the prophylactic
regimens, 63 were considered in this analysis because they
received> 180 days of prophylaxis. Of these 63 patients, 59
received prophylaxis for 365 days# 10%. The characteristics
of the cohort included are detailed in ►Table 1.
During the prophylaxis period of the study, 22 patients
(34.9%) did not report any bleeds, whereas the remaining 41
patients experienced at least one bleed. A total of 26 patients
(41.3%) experienced at least one spontaneous joint bleed,
whereas 37 patients (58.7%) did not record any spontaneous
joint bleeds during the study period on prophylaxis. At study
entry, only 3 patients had no target joints and 60 patients had
between 1 and 10 target joints (median, 3).
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Bleed Details
A total of 229 bleeds were considered in this analysis, of
which 200were joint bleeds and 105were spontaneous joint
bleeds. The location, severity, and etiology of the bleeds are
described in ►Table 2.
Estimated FVIII Levels in Relation to Reported Bleeds
The estimated FVIII levels at which bleeds occurred against
the time at which bleeds occurred after infusion of anti-
hemophilic factor (recombinant) are shown in►Fig. 1, for all
bleeds observed during prophylaxis. Bleeds were reported at
FVIII levels up to 60 IU/dL, with spontaneous joint bleeds
only occurring below a FVIII level of 35 IU/dL.
Relationship between Estimated FVIII Levels and
Bleeds
Theproportionofpatientswhowouldexperiencezerobleeds in
a year if their trough FVIII levels were maintained above the
potentially effective trough level was estimated for each bleed
type, using the pragmatic and conservative approaches
described earlier. This information is presented by bleed type
in ►Tables 3 and 4. It is also presented graphically using
Kaplan–Meiercurvesforallbleedsandspontaneous jointbleeds
in ►Figs. 2 and 3, respectively. For each bleed type, results are
presented under the pragmatic and conservative approach on
the same plot, for comparison.
The analysis that utilized the pragmatic approach indicated
that 40, 43, and 63%of thepatientswere expected to have zero
all bleeds, joint bleeds, or spontaneous joint bleeds while
maintaining a trough level of 1 IU/dL. With the conservative
approach, similar outcomeswere derived at around3 IU/dL for
all bleeds and joint bleeds, and at 5 IU/dL for spontaneous joint
bleeds. A measurable level of 1 IU/dL provided substantial
benefit in the prevention of bleeds, and higher levels were
associated with smaller incremental benefits.
When a modeled FVIII level was set as a trough level
between 1 and 10 IU/dL, under the pragmatic approach, a
1 IU/dL increase in FVIII level was associated with a 2%
increase in the number of patients who might achieve zero
bleeds in a year. No bleeds occurred between estimated FVIII
trough levels of 10 and 12 IU/dL.
Further, there was no obvious difference in the estimates
between the two approaches when the modeled FVIII level
exceeded 10 IU/dL, the level at which near maximal efficacy
was seen. Continuing with the pragmatic approach, beyond a
modeled FVIII level of 10 IU/dL, for every 10 IU/dL increase, we
might expect on average a 10 to 15% change in the proportion
of patients achieving zero bleeds in a year, depending on the
bleed type; after 30% there was minimal gain. The proportion
predictions at the higher FVIII levels had wide confidence
intervals, and indeed, the potential for misreporting pain as
bleeds increased with increasing FVIII levels.
Discussion
In this post hoc analysis of patients with severe hemophilia A
with multiple target joints initiated on tertiary prophylaxis,
Table 1 Patient characteristics
Parameter Mean# SD Median (range)
Age (y) 30.32# 12.61 28 (7–59)
Weight (kg) 70.98# 15.47 71 (18.7–120)
Number of
target jointsa
3.49# 2.12 3 (0–10)
FVIII t½ for the group 12.18# 3.21 12.25
(7.28–21.89)
On-demand period
ABR of all bleeds 50.04# 21.56 45.89
(13.04–121.13)
ABR of joint bleeds 43.53# 21.00 39.13
(6.52–115.54)
ABR of spontaneous
joint bleeds
31.90# 18.52 29.94
(0–91.31)
Prophylaxis period
ABR of all bleeds 2.10# 4.22 0 (0–17.11)
ABR of joint bleeds 1.94# 3.99 0 (0–17.11)
ABR of spontaneous
joint bleeds
0.97# 2.21 0 (0–10.23)
Abbreviations: ABR, annualized bleeding rate; FVIII, factor VIII; SD,
standard deviation; t½, half-life.
aTarget joints were defined as joints in which! 4 hemorrhages had
occurred within a period of 6 months, or in which> 20 lifetime
hemarthroses had occurred.
Table 2 Bleed details by location and severity
Bleed location, n (%)
Total Joint Nonjoint
Type
Total 229 200 29
Spontaneous 116 105 11
Traumatic 113 95 18
Severity assessment for total bleeds (n¼ 229)
Mild 78 (34.1) 59 (29.5) 19 (65.5)
Moderate 127 (55.5) 121 (60.5) 6 (21.0)
Severe 15 (6.6) 14 (7.0) 1 (3.5)
Missing 9 (3.9) 6 (3.0) 3 (10.0)
Severity assessment for spontaneous bleeds (n¼ 116)
Mild 36 (31.0) NA NA
Moderate 71 (61.2) NA NA
Severe 7 (6.0) NA NA
Missing 2 (1.7) NA NA
Severity assessment for traumatic bleeds (n¼ 113)
Mild 42 (37.2) NA NA
Moderate 56 (49.6) NA NA
Severe 8 (7.1) NA NA
Missing 7 (6.2) NA NA
Abbreviation: NA, not available.
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the proportions of the cohort that would have been bleed
free if the estimated FVIII level of 1 IU/dL was set as the
lowest FVIII level of clinical interest (i.e., trough level) were
40% for all bleeds, 43% for joint bleeds, and 63% for sponta-
neous joint bleeds.
For all bleeds, a 1% rise in themodeled FVIII level between
1 and 10 IU/dL increased the proportion of the cohort
achieving zero all bleeds by approximately 2%. At a modeled
FVIII level of 10 IU/dL using the pragmatic approach, 60.3% of
patients recently initiated on tertiary prophylaxis were
Fig. 1 Predicted factor VIII (FVIII) activity levels at the time of each bleed.
Table 3 Pragmatic approach for the prediction of zero all bleeds, joint bleeds, and spontaneous joint bleeds in a year, according to
estimated FVIII levels
Estimated FVIII activity
level (IU/dL)
Patients with zero bleeds (%)
All bleeds Joint bleeds Spontaneous joint bleeds
Proportion 95% CI for
proportion
Proportion 95% CI for
proportion
Proportion 95% CI for
proportion
1 39.7 28.5 52.0 42.9 31.4 55.1 63.5 51.2 74.3
3 44.4 32.9 56.7 47.6 35.8 59.7 68.3 56.0 78.4
5 50.8 38.8 62.7 54.0 41.8 65.7 71.4 59.3 81.1
10 60.3 48.0 71.5 63.5 51.2 74.3 79.4 67.8 87.5
12 60.3 48.0 71.5 63.5 51.2 74.3 79.4 67.8 87.5
15 66.7 54.4 77.1 69.8 57.6 79.8 85.7 75.0 92.3
20 74.6 62.7 83.7 76.2 64.4 85.0 88.9 78.8 94.5
30 88.9 78.8 94.5 88.9 78.8 94.5 98.4 91.5 99.7
40 90.5 80.7 95.6 90.5 80.7 95.6 100.0 94.3 100.0
50 95.2 86.9 98.4 95.2 86.9 98.4 100.0 94.3 100.0
60 100.0 94.3 100.0 100.0 94.3 100.0 100.0 94.3 100.0
Abbreviations: CI, confidence interval; FVIII, factor VIII.
Note: The estimated FVIII level is the assumed effective FVIII level specific to the individual and type of bleed.
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expected to have zero all bleeds, 63.5% were estimated to
have zero joint bleeds, and 79.4%were estimated to have zero
spontaneous joint bleeds. Above a modeled FVIII level of
10 IU/dL, the reductions in bleeds were less substantial.
However, bleeds were also reported atmuch higher modeled
FVIII levels in some patients, even outside the range of FVIII
levels associated with hemophilia (0–40 IU/dL).
These data are similar to those published in another post
hoc analysis of 143 previously treated patients in three pivotal
clinical studies of antihemophilic factor (recombinant).10 In
the pivotal antihemophilic factor (recombinant) cohort, the
median ABR in children was 3.1 (patients aged 1–6 years,
n¼ 44, arthropathy 2%, adherence 89%, zero ABR 25%) and in
adolescents and adults it was similar at a median of 3.3
(patients aged 10–65 years, n¼ 99, arthropathy 67%, adher-
ence 78%, zero ABR 16%). Amultivariate analysis predicted the
probability of having zero bleeds when patients spent no time
with FVIII levels< 1 IU/dL during prophylaxis to be 55% for
adults (vs. 40% in this analysis, where the regimen was
optimized to achieve a trough level of 1%) and 90% for children.
Table 4 Conservative approach for the prediction of zero all bleeds, joint bleeds, and spontaneous joint bleeds in a year, according
to estimated FVIII levels
Estimated FVIII
activity level (IU/dL)
Patients with zero bleeds (%)
All bleeds Joint bleeds Spontaneous joint bleeds
Proportion 95% CI for
proportion
Proportion 95% CI for
proportion
Proportion 95% CI for
proportion
1 19.1 11.3 30.4 19.1 11.3 30.4 27.0 17.6 39.0
3 36.5 25.7 48.9 36.5 25.7 48.9 50.8 38.8 62.7
5 47.6 35.8 59.7 49.2 37.3 61.2 63.5 51.2 74.3
10 60.3 48.0 71.5 61.9 49.6 72.9 77.8 66.1 86.3
12 60.3 48.0 71.5 61.9 49.6 72.9 77.8 66.1 86.3
15 66.7 54.4 77.1 69.8 57.6 79.8 85.7 75.0 92.3
20 74.6 62.7 83.7 76.2 64.4 85.0 88.9 78.8 94.5
30 88.9 78.8 94.5 88.9 78.8 94.5 98.4 91.5 99.7
40 90.5 80.7 95.6 90.5 80.7 95.6 100.0 94.3 100.0
50 95.2 86.9 98.4 95.2 86.9 98.4 100.0 94.3 100.0
60 100.0 94.3 100.0 100.0 94.3 100.0 100.0 94.3 100.0
Abbreviations: CI, confidence interval; FVIII, factor VIII.
Note: The estimated FVIII level is the assumed effective FVIII level specific to the individual and type of bleed.
Fig. 3 Comparison of the pragmatic and conservative approaches,
showing the proportion of the cohort predicted to have zero spon-
taneous joint bleeds according to factor VIII (FVIII) levels of clinical
interest (the minimum effective estimated FVIII level specific to the
individual and the type of bleed).
Fig. 2 Comparison of the pragmatic and conservative approaches,
showing the proportion of the cohort predicted to have zero all bleeds
according to factor VIII (FVIII) levels of clinical interest (the minimum
effectiveestimatedFVIII level specific to the individualand the typeofbleed).
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The increasing bleed rate in adolescents and adults in addition
to its association with increasing time spent at a FVIII
level< 1 IU/dL was also inversely related to the average fre-
quency of infusions, which is logical if one considers that
frequency and adherence to frequency have the greatest
impact on trough levels. The higher ABRs in adolescents and
adults may potentially be related to their physical activity and
arthropathy, implying a potential role for other nonhemato-
logical factors in bleed prevention, particularly in adolescents
and adults.18
One nonhematological factor that has been studied in
children with hemophilia receiving regular prophylaxis is
the transient increase in the risk of bleeding associated with
vigorous physical activity.19 The authors noted that most
bleeds associated with physical activity were manifest
within 1 hour of activity and the National Hemophilia
Foundation risk categorization was used to categorize phys-
ical activity.20 Category 2 and 3 physical activities were
associated with a transient increase in the risk of bleeding,
with odds ratios of 2.7 and 3.7, respectively. The data
demonstrate a moderate increase in relative risk, however,
the absolute increase was low. Further, the bleeding inci-
dence was lower by 2% for every 1 IU/dL increase in clotting
factor level. These results are similar to those demonstrated
in this cohort with the pragmatic approach, where every
1 IU/dL increase in the modeled FVIII level> 1 IU/dL was
associated with a lower bleed rate and a 2% increase in the
proportion of the cohort predicted to have zero joint bleeds,
both spontaneous and traumatic; however, the nature of
activity responsible for the traumatic bleeds was not cate-
gorized in the study.
A major limitation of this analysis is the assumption that
bleed risk is independent of time and activity. Other con-
founding factors in the analysis include the different trough
levels and bleeding risk per patient, the varying observation
period per patient, and the need for imputation to provide
bleed-rate estimates in relation to set FVIII levels. Other
limitations include the presence of active target joints at
enrollment, because the Kaplan–Meier estimates in this
analysis are for the first year of tertiary prophylaxis and
estimates for subsequent years may change, as it is well
known that the cohort’smedian ABR decreasedwith increas-
ing length of time spent on prophylaxis.21 In addition, all
bleeds were self-reported and, in patients with chronic
arthropathy, it is not uncommon for arthritic pain to be
misinterpreted as early bleeds: previous studies have shown
that this may be the case in as many as one-third of all
bleeds.22,23 Further, patients have been educated to treat
when in doubt and it is likely that the reported bleeds at high
FVIII levels were probably not true bleeds. Similarly, there
may be underreporting of bleeding events toward the tail
end of the prophylaxis period when the next infusion was
due. This limitation applies to almost all studies in the field.
The analysis confirms that the greatest benefit is seen at
FVIII levels of approximately 1 IU/dL, which is the first target
in the prophylactic management of hemophilia A.1,10 The
analysis also confirms the results from the post hoc analysis
of the antihemophilic factor (recombinant) pivotal cohort10
and is congruent with the findings published on the natural
history of joint bleeding in patientswithmild, moderate, and
severe hemophilia receiving prophylaxis.12 It also supports
the role of other factors in the development of bleeds,
potentially including activity and trauma.9,18 This multifac-
torial pathogenesis of bleeds underlies the philosophy of
personalized prophylaxis that considers other determinants
in designing the optimal prophylaxis regimen, including
personalized trough levels for patients.9,24,25
Higher peak and trough levels can be achieved either
empirically and through the calculation of half-life with
formal PK analysis, or through Bayesian analysis.16,26–30
The benefit of higher trough levels has been observed in
post hoc analyses of various cohort studies. In addition, this
hypothesis was tested in a randomized controlled trial
comparing trough levels of 1 to 3 IU/dL versus 8 to 12 IU/dL
(NCT02585960).31
In conclusion, this post hoc analysis confirms previous
observations with regard to the FVIII level of 1 IU/dL where
maximum benefit is seen. However, to prevent all spontane-
ous joint bleeds, some patients may require higher FVIII
levels, which can be determined on the basis of clinical
outcomes and PK evaluation.
What is known about this topic?
• Prophylaxis in severe hemophilia A increasingly tar-
gets factor VIII (FVIII) troughs! 1 IU/dL.
• Data on tertiary prophylaxis can be used tomodel FVIII
trough levels and zero bleeding.
What does this paper add?
• Modeling showed greatest benefit with FVIII trough
levels of 1–3 IU/dL.
• FVIII> 3 IU/dL was associated with an extra 2% of
patients with no bleeds per 1 IU/dL rise.
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